Testosterone Therapy Dosing, Monitoring, and Safety Guidelines

Gender‑Affirming Testosterone Therapy (Transgender Men/Transmasculine Individuals)

Target serum testosterone: Standard masculinizing regimens are intended to raise serum testosterone into the typical cisgender male reference range. 1
Low‑dose option for gradual change: For patients who prefer a more androgynous appearance, low‑dose testosterone can be used to achieve partial masculinization. 1
Hemoglobin response: Standard‑dose therapy raises hemoglobin to the male reference range within approximately three months. 1
Safety monitoring for masculinizing doses: Clinicians should watch for polycythemia, reductions in HDL cholesterol, androgenic alopecia, and acne in individuals receiving masculinizing testosterone. 1
Irreversible changes: Voice deepening and the development of body/facial hair are permanent even if testosterone therapy is stopped. 1

Formulation preference: Injectable testosterone cypionate is not the preferred formulation for cisgender women with androgen deficiency or hypoactive sexual desire; transdermal testosterone cream is recommended instead. 2
Product quality: Commercially manufactured testosterone products are favored over compounded preparations because of consistent potency and quality. 2
Advantages of transdermal delivery: Transdermal preparations provide stable daily testosterone levels and allow easier dose titration. 2

Initial serum testosterone check: Measure serum testosterone 2–3 months after therapy initiation or after any dose change to confirm therapeutic levels. 2
Ongoing monitoring interval: Once stable levels are achieved, repeat testosterone assessments every 6–12 months are adequate. 2
Annual clinical review: Conduct an annual review focusing on treatment adherence, safety, and any adverse effects. 2

Contraindication: Testosterone should not be prescribed to individuals with a history of breast cancer. 2
Maximum treatment duration: Limit therapy to a maximum of 24 months due to limited long‑term safety data. 2
Drug interaction caution: Avoid co‑prescribing anti‑androgenic progestins in women with premature ovarian insufficiency, as this can worsen hypo‑androgenism. 2
Application counseling: When using transdermal testosterone, educate patients on proper application technique and hand washing to prevent inadvertent transfer to partners or children. 2